Skip to contentI
IDEAYA Biosciences, Inc.
I
IDYAIDEAYA Biosciences, Inc. Q1 2023 · 10-Q
Revenue$7.88M$7.88M−30.6% vs Q1 2022 Net Income-$23.64M-$23.64MN/M vs Q1 2022 EPS Diluted-$0.49-$0.49N/M vs Q1 2022 Operating Income-$26,279,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IDEAYA Biosciences, Inc. · CIK 1676725 · Engraved from SEC EDGAR
Free Cash Flowderived-$27,885,000N/M Margins · derivedOperating margin-333.5%−208.3 pt vs Q1 2022
Net margin-300.0%−176.6 pt vs Q1 2022
ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end